Merck & Co., Inc. (FRA:6MK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 171.37B |
| Revenue (ttm) | 59.14B |
| Net Income (ttm) | 16.13B |
| Shares Out | n/a |
| EPS (ttm) | 6.36 |
| PE Ratio | 10.62 |
| Forward PE | 8.46 |
| Dividend | 2.93 (4.34%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 5,194 |
| Average Volume | 4,704 |
| Open | 66.70 |
| Previous Close | 66.60 |
| Day's Range | 66.60 - 68.10 |
| 52-Week Range | 65.50 - 125.60 |
| Beta | n/a |
| RSI | 36.73 |
| Earnings Date | Apr 24, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Tech sector leads: Nvidia and Amazon surge amidst healthcare tumble
Sector Overview The stock market is exhibiting diverse patterns today, with notable sector-specific performance highlighting varying investor outlooks. Technology Storms Ahead: The technology sector i...
Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research across more than 25 types of cancer and multiple treatment settings from the company’s broad and d...
Research on Novel Treatment Approaches and Scientific Advances From Merck's Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research across more than 25 types of cancer and multiple trea...
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas
Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.
Drugmakers are spared worst-case drug pricing scenario for now
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Stocks making the biggest moves midday: Amazon, Alibaba, Merck, Five Below, Nike and more
These are the stocks posting the largest moves in midday trading.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Trump says executive order will slash the cost of prescription drugs
President Donald Trump signed an executive order targeting the cost of prescription drugs. Prices will be cut by as much as 80%, and some immediately, he said at a press conference.
Trump Announces Executive Order to Lower Drug Prices
President Donald Trump says he'll sign an executive order that will lower drug prices for Americans. The order aims to align patient costs with lower prices paid abroad, focusing on Medicare and weigh...
White House release details on executive order on drug prices: Here's what to know
CNBC's Eamon Javers reports on the latest news.
Pfizer, Eli Lilly, Merck and Other Pharma Stocks Fall as Trump Targets Lower Drug Prices
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices
Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.
European pharma stocks follow Asia peers down as Trump moves to cut prices
European drugmakers stocks fell in early trading on Monday after U.S. President Donald Trump said he would sign an executive order on reducing prescription drug and pharmaceutical prices.
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
Paris, May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien E...
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volati...
Tesla and Google surge as healthcare sector falters in mixed market
Today's Market Overview The US stock market presents a mixed picture today, with notable performances in the consumer cyclical and communication services sectors. Giants like Tesla and Google are emer...
Merck boosts U.S. investments with $895M expansion in Kansas site
Merck Animal Health announces $895 million investment in Kansas
Merck Animal Health, a unit of Merck , said on Thursday it would invest $895 million to expand its manufacturing facility in De Soto, Kansas.
Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), and Kansas Governor Laura Kelly jointly announc...
Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), and Kansas Gover...
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025, including transactions that may have been perfectly timed during a market dip. Here's the latest transactions made by the c...
Merck to Participate in the Bank of America 2025 Global Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Marjorie Green, senior vice president and head of...